Growth Metrics

Regenxbio (RGNX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 176.27%.

  • Regenxbio's EBIT Margin rose 802800.0% to 176.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 96.04%, marking a year-over-year increase of 1955400.0%. This contributed to the annual value of 280.03% for FY2024, which is 170900.0% up from last year.
  • Latest data reveals that Regenxbio reported EBIT Margin of 176.27% as of Q3 2025, which was up 802800.0% from 296.26% recorded in Q2 2025.
  • In the past 5 years, Regenxbio's EBIT Margin ranged from a high of 78.66% in Q4 2021 and a low of 408.8% during Q1 2024
  • For the 5-year period, Regenxbio's EBIT Margin averaged around 230.81%, with its median value being 242.14% (2024).
  • In the last 5 years, Regenxbio's EBIT Margin tumbled by -2629700bps in 2022 and then soared by 4224300bps in 2025.
  • Regenxbio's EBIT Margin (Quarter) stood at 78.66% in 2021, then plummeted by -334bps to 184.31% in 2022, then crashed by -56bps to 287.68% in 2023, then grew by 16bps to 242.14% in 2024, then rose by 27bps to 176.27% in 2025.
  • Its EBIT Margin stands at 176.27% for Q3 2025, versus 296.26% for Q2 2025 and 13.62% for Q1 2025.